论文部分内容阅读
溶栓法治疗缺血性脑卒中最近受到普遍重视,尤其是当与急救医疗系统(症状发作后尽快识别,运送,评价和早期治疗患者)联合治疗时。最近完成了对患者分别在症状出现后90min内和91～180min之间用人重组组织型纤溶酶原激活剂(rt-PA)治疗的剂量递增安全性研究。这项研究提示在缺血性脑卒中发作1h后静注rt-PA,用药剂量<0.95mg/kg,可降低发生严重的出血性并发症的危险性。然而对缺血性脑卒中患者在病程早期很少能获得有价值的
Thrombolytic therapy for ischemic stroke has received widespread attention lately, especially when combined with emergency medical systems that identify, deliver, evaluate, and treat patients as soon as symptoms develop. A dose-escalation safety study of patients treated with human recombinant tissue-type plasminogen activator (rt-PA) was recently completed within 90 min and 91-180 min after onset of symptoms, respectively. This study suggests that intravenous injection of rt-PA 1 h after ischemic stroke may reduce the risk of serious hemorrhagic complications with doses <0.95 mg / kg. However, patients with ischemic stroke seldom gain valuable early stage disease